A Phase II, Open-Label, Multicenter Trial to Assess the Efficacy and Safety of the PARP Inhibitor, Olaparib, Alone in Previously-Treated Patients With Stage IV, Measurable Colorectal Cancer, Stratified by MSI Status

Inclusion Criteria:

- Patients will have measurable disseminated colorectal cancer that is incurable by
surgery

- Patients will have had tumor progression following standard combination front-line or
second-line chemotherapy.

- CRC patients who have relapsed or recurrent disease within six months after
completing adjuvant or neoadjuvant chemotherapy

Exclusion Criteria:

- Previous treatment with PARP inhibitors, including olaparib.

- Patients with symptomatic, uncontrolled brain metastases.

- Patients receiving any chemotherapy, radiotherapy (except for palliative reasons),
within 4 weeks from the last dose prior to study entry (or a longer period depending
on the defined characteristics of the agents used).

- Patients who are unable to swallow orally administered medication.